Moffitt Researchers Help Lead Efforts to Find New Genetic Links to Prostate Cancer

“Researchers at Moffitt Cancer Center, including Center Director Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi Lin, Ph.D., have discovered 23 new regions of the genome that influence the risk for developing prostate cancer, according to a study published Sept. 14 in Nature Genetics.

“Prostate cancer is the most common non-skin cancer in American men. About 1 in 6 men will be diagnosed with the disease in his lifetime. Family history is the strongest risk factor. A man with one close relative, a brother or father with prostate cancer is twice as likely to develop the disease as a man with no family history of prostate cancer.

“This study brings the number of genetic variants linked to prostate cancer to 100. Testing for those variants can identify men with a risk of the disease that is almost six times higher than average.”


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Molecular Tumor Board Helps in Advanced Cancer Cases

With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.

Editor’s note: Learn more about personalized medicine and molecular (genetic) testing on our website.


Molecular Tumor Board Helps in Advanced Cancer Cases

With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.

Editor’s note: Learn more about personalized medicine and molecular (genetic) testing on our website.


Molecular Tumor Board Helps in Advanced Cancer Cases

With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.

Editor’s note: Learn more about personalized medicine and molecular (genetic) testing on our website.


Cancer ‘Miracle’ Patients Studied Anew for Disease Clues

“The history of oncology is rife with reports of patients with advanced cancer who staged miraculous recoveries.

“Now scientists are starting to use sophisticated DNA sequencing technology to determine if these “exceptional responders” carry gene variations that can lead to new treatment approaches, better targeted therapies or even the re-emergence of experimental drugs once deemed failures.

“The mystery surrounding Jan Crisitello, a 70-year-old grandmother of four, is a case in point. Five years ago, 29 patients with advanced melanoma enrolled in a trial of a drug under development by Pfizer Inc. (PFE) Only one, Crisitello, came away with her cancer in remission. Now, she is being studied to see how her unique genome may have interacted with the drug to spur her recovery.”

Editor’s note: To learn more about personalized medicine, click here.


Cancer ‘Miracle’ Patients Studied Anew for Disease Clues

“The history of oncology is rife with reports of patients with advanced cancer who staged miraculous recoveries.

“Now scientists are starting to use sophisticated DNA sequencing technology to determine if these “exceptional responders” carry gene variations that can lead to new treatment approaches, better targeted therapies or even the re-emergence of experimental drugs once deemed failures.

“The mystery surrounding Jan Crisitello, a 70-year-old grandmother of four, is a case in point. Five years ago, 29 patients with advanced melanoma enrolled in a trial of a drug under development by Pfizer Inc. (PFE) Only one, Crisitello, came away with her cancer in remission. Now, she is being studied to see how her unique genome may have interacted with the drug to spur her recovery.”

Editor’s note: To learn more about personalized medicine, click here.